Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - hepatitis b, surface antigen, recombinant - suspension for injection in pre-filled syringe - hepatitis b surface antigen, recombinant 10 µg - vaccines

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - hepatitis b, surface antigen, recombinant - suspension for injection in pre-filled syringe - hepatitis b surface antigen, recombinant 20 µg - vaccines

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - hepatitis b, surface antigen, recombinant - suspension for injection - hepatitis b surface antigen, recombinant 20 µg/l - vaccines

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - hepatitis b, surface antigen, recombinant - suspension for injection - hepatitis b surface antigen, recombinant 20 µg/l - vaccines

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - hepatitis a, virus, inactivated, elisa - suspension for injection in pre-filled syringe - hepatitis a virus (inactivated) 1440 elisa unit/dose - vaccines

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hpv type 11 l1 protein; hpv type 16 l1 protein; hpv type 18 l1 protein; hpv type 31 l1 protein; hpv type 33 l1 protein; hpv type 45 l1 protein; hpv type 52 l1 protein; hpv type 58 l1 protein; hpv type 6 l1 protein - suspension for injection - hpv type 58 l1 protein 20 mcg / 0.5 ml; hpv type 52 l1 protein 20 mcg / 0.5 ml; hpv type 45 l1 protein 20 mcg / 0.5 ml; hpv type 33 l1 protein 20 mcg / 0.5 ml; hpv type 31 l1 protein 20 mcg / 0.5 ml; hpv type 18 l1 protein 40 mcg / 0.5 ml; hpv type 16 l1 protein 60 mcg / 0.5 ml; hpv type 11 l1 protein 40 mcg / 0.5 ml; hpv type 6 l1 protein 30 mcg / 0.5 ml - papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) - gardasil 9 is indicated for active immunisation of individuals at the age of 9-45 years old against the following hpv diseases:• premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine hpv types• genital warts (condyloma acuminata) caused by specific hpv types.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis b vaccine, rdna 10 µg/ml - suspension for injection - 10 mcg/ml - active: hepatitis b vaccine, rdna 10 µg/ml excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax formaldehyde potassium thiocyanate sodium chloride water for injection - immunisation against infection caused by all known subtypes of hepatitis b virus. hbvaxpro should also prevent hepatitis d (caused by the delta virus) since hepatitis d does not occur in the absence of hepatitis b infection.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis b vaccine, rdna 40 µg/ml - suspension for injection - 40 mcg/ml - active: hepatitis b vaccine, rdna 40 µg/ml excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax formaldehyde potassium thiocyanate sodium chloride water for injection - immunisation against infection caused by all known subtypes of hepatitis b virus. hbvaxpro should also prevent hepatitis d (caused by the delta virus) since hepatitis d does not occur in the absence of hepatitis b infection.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - measles vaccine 1000 tcid50 (at end of expiry); mumps vaccine 12500 tcid50 (at end of expiry); rubella vaccine 1000 tcid50 (at end of expiry) - suspension for injection - active: measles vaccine 1000 tcid50 (at end of expiry) mumps vaccine 12500 tcid50 (at end of expiry) rubella vaccine 1000 tcid50 (at end of expiry) excipient: dibasic potassium phosphate dibasic sodium phosphate monohydrate eagle minimum essential medium gelatin medium 199 monobasic potassium phosphate monobasic sodium phosphate monohydrate monosodium glutamate neomycin phenolsulfonphthalein sodium bicarbonate sorbitol sucrose water for injection - m-m-r ii is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.

Ireland - English - HPRA (Health Products Regulatory Authority)

instituto grifols s.a. - human plasma protein - solution for infusion - 50 gram(s)/litre - blood substitutes and plasma protein fractions; albumin